One of the most relevant brands among our more than 25 partners is TargetMol

α-Amylase/α-Glucosidase-IN-14 is an orally bioactive inhibitor of α-amylase and α-glucosidase, with IC50 values of 45.53 μM and 27.73 μM, respectively.

<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>

Deacetyl-7-aminocephalosporanic acid serves as a crucial intermediate in the production of β-lactam broad-spectrum cephalosporin antibiotics.

RGB110 (Compound 10d) is a PROTAC inhibitor of D-dopachrome tautomerase (D-DT) with an IC50 of 5.9 μM. It does not induce the degradation of D-DT.

<p>EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.</p>

CTL26 is an effective, orally active α-glucosidase inhibitor, with an IC50 value of 2.81 µM, demonstrating antidiabetic properties.

<p>MC-ND-18 is an ATTEC degrader that facilitates the degradation of NLRP3 via autophagy, exhibiting a DC50 of 125.5 nM in THP-1 cells. It is composed of an NLRP3 ligand, a linker, and an LC3 ligand.</p>

KRN7000 analog 1 stimulates a strong Th1-biased immune response by inducing interferon-γ (IFN-γ) and reducing interleukin-4 (IL-4). This compound shows potential as an antitumor agent and vaccine adjuvant.

M 15 liquid crystals are a member of the oxycyanobiphenyl family, which exhibits a liquid crystalline phase in the temperature range of 47-67.5℃.

<p>P-gp inhibitor 23 (compound 14F) is an effective inhibitor of both P-gp and CYP3A4, with an EC50 of 28 nM for P-gp and an IC50 of 223 nM for CYP3A4.</p>

<p>PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) with an IC50 of 700 nM. It forms hydrogen bonds with amino acid residues of Des1, while its cyclopropenone group may coordinate with the iron center, stabilizing its binding at Des1's active site. This inhibits the ceramide biosynthesis pathway, preventing dihydroceramide (dhCer) from converting into ceramide. PR280 can be used in research related to sphingolipid metabolism disorders, including cancer and metabolic diseases.</p>

Deacetyldiltiazem is a metabolite product of Diltiazem which is a coronary vasodilator, and is present in the plasma of individuals taking Diltiazem.

KSK-104 exhibits potent antibacterial activity against Mycobacterium tuberculosis, with a minimum inhibitory concentration (MIC) of 0.78 μM. Its mechanism of action primarily involves the synthesis and salvage pathway of pyridoxal 5'-phosphate (PLP), as well as PLP-dependent enzymes and the oxidative stress network. KSK-104 is a promising candidate for developing novel anti-tuberculosis drugs targeted at drug-resistant strains of Mycobacterium tuberculosis.

hCAIX-IN-20 (compound APBS-5m) is a potent inhibitor of carbonic anhydrase IX (hCA IX), with a Ki of 2.7 nM, playing a significant role in cancer research.

PROTACBRD4 Degrader-26 (PROTAC-2) is a photo-regulated PROTAC designed to degrade BRD4, achieving 80% degradation efficiency at a concentration of 1 μM. This compound can be inactivated by ultraviolet light.

Ac-macropa is a conjugate of Actinium-225 that targets PSMA, and it is useful for researching prostate cancer.

<p>Conjugated linoleic acid is found in ruminant meat and dairy, made via rumen bio-hydrogenation, mainly as 9cis, 11trans isomer.</p>

SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active, non-covalent inhibitor of SARS-CoV-2 Mpro, with an EC50 value of 1.35 μM. It is applicable for research related to COVID-19.

Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible inhibitor of kidney-type glutaminase (KGA). It binds to the glutamine binding site and forms a covalent bond with the cysteine residue at the active site. This compound selectively kills triple-negative breast cancer (TNBC) cells without being cytotoxic to control cell lines. KGA is an enzyme that regulates glutamine metabolism and is associated with tumor malignancy.

<p>Lenalidomide-5-bromopentanamide is a component of PROTACATR degrader-2, serving as an E3 ligase ligand-linker conjugate. It is composed of the CRBN ligand Lenalidomide and the linker 5-Bromopentanoyl chloride. This compound is utilized in the synthesis of PROTACs.</p>